

# Otitis Media Treatment Pipeline Review H1 2016

*Otitis Media - Pipeline Review, H2 2016*

PUNE, INDIA, August 30, 2016  
/EINPresswire.com/ -- Summary

'[Otitis Media](#) - Pipeline Review, H2 2016', provides an overview of the Otitis Media pipeline landscape. The report provides comprehensive information on the therapeutics under development for Otitis Media, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Otitis Media and features dormant and discontinued projects.

Complete report details @  
[https://www.wiseguyreports.com/reports/619242-](https://www.wiseguyreports.com/reports/619242-otitis-media-pipeline-review-h2-2016)

[otitis-media-pipeline-review-h2-2016](https://www.wiseguyreports.com/reports/619242-otitis-media-pipeline-review-h2-2016)

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Request a sample report @ <https://www.wiseguyreports.com/sample-request/619242-otitis-media-pipeline-review-h2-2016>

## Scope

- The report provides a snapshot of the global therapeutic landscape of Otitis Media
- The report reviews pipeline therapeutics for Otitis Media by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-



registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Otitis Media therapeutics and enlists all their major and minor projects
- The report assesses Otitis Media therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Otitis Media

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Otitis Media
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Otitis Media pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Make an enquiry before buying this Report @ <https://www.wiseguyreports.com/enquiry/619242-otitis-media-pipeline-review-h2-2016>

Key points in table of content

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Otitis Media Overview 8

Therapeutics Development 9

Pipeline Products for Otitis Media - Overview 9

Pipeline Products for Otitis Media - Comparative Analysis 10

Otitis Media - Therapeutics under Development by Companies 11

Otitis Media - Therapeutics under Investigation by Universities/Institutes 12

Otitis Media - Pipeline Products Glance 13

Late Stage Products 13

Clinical Stage Products 14

Early Stage Products 15

Otitis Media - Products under Development by Companies 16

Otitis Media - Products under Investigation by Universities/Institutes 17

Otitis Media - Companies Involved in Therapeutics Development 18

Cellceutix Corporation 18

ContraFect Corporation 19

GlaxoSmithKline Plc 20  
Lee's Pharmaceutical Holdings Limited 21  
Madam Therapeutics B.V. 22  
Merck & Co., Inc. 23  
MerLion Pharmaceuticals Pte Ltd 24  
Oticpharma Ltd 25  
Otonomy, Inc. 26  
Yuhan Corporation 27  
Otitis Media - Therapeutics Assessment 28  
Assessment by Monotherapy Products 28  
Assessment by Combination Products 29  
Assessment by Target 30  
Assessment by Mechanism of Action 32  
Assessment by Route of Administration 34  
Assessment by Molecule Type 36  
Drug Profiles 38  
(dexamethasone acetate + piperacillin sodium + tazobactam sodium) - Drug Profile 38  
Product Description 38  
Mechanism Of Action 38  
R&D Progress 38  
betahistine dihydrochloride - Drug Profile 39  
Product Description 39  
Mechanism Of Action 39  
R&D Progress 39  
brilacidin tetrahydrochloride - Drug Profile 40  
Product Description 40  
Mechanism Of Action 40  
R&D Progress 40  
CF-303 - Drug Profile 49  
Product Description 49  
Mechanism Of Action 49  
R&D Progress 49  
CF-309 - Drug Profile 50  
Product Description 50  
Mechanism Of Action 50  
R&D Progress 50  
ciprofloxacin hydrochloride - Drug Profile 51  
Product Description 51  
Mechanism Of Action 51  
R&D Progress 51  
ciprofloxacin hydrochloride SR - Drug Profile 55  
Product Description 55  
Mechanism Of Action 55  
R&D Progress 55  
finafloxacin - Drug Profile 56  
Product Description 56  
Mechanism Of Action 56  
R&D Progress 56  
GSK-2189242A - Drug Profile 59  
Product Description 59  
Mechanism Of Action 59  
R&D Progress 59

pazufloxacin - Drug Profile 60

Product Description 60

Mechanism Of Action 60

R&D Progress 60

PCL-1402 - Drug Profile 61

Product Description 61

Mechanism Of Action 61

R&D Progress 61

Recombinant Peptide to Inhibit DNA for Otitis Media and Haemophilus Influenzae Infections - Drug Profile 62

Product Description 62

Mechanism Of Action 62

R&D Progress 62

Small Molecules for Otitis Media - Drug Profile 63

Product Description 63

Mechanism Of Action 63

R&D Progress 63

Buy this report @ [https://www.wiseguyreports.com/checkout?currency=one\\_user-USD&report\\_id=619242](https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=619242)

Norah Trent

wiseguyreports

+1 646 845 9349 / +44 208 133 9349

email us here

---

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2016 IPD Group, Inc. All Right Reserved.